Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42

Morgan Stanley analyst Matthew Harrison has maintained an Overweight rating on Denali Therapeutics (NASDAQ: DNLI) and raised the price target from $40 to $42.